A Phase I, Single-Centre, Randomised, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics After Multiple Oral Doses of AZD2066 in Japanese Healthy Male Subjects.

Trial Profile

A Phase I, Single-Centre, Randomised, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics After Multiple Oral Doses of AZD2066 in Japanese Healthy Male Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Aug 2009

At a glance

  • Drugs AZD 2066 (Primary)
  • Indications Diabetic neuropathies; Gastro-oesophageal reflux; Neuropathic pain
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 26 Aug 2009 Actual patient number (132) added as reported by ClinicalTrials.gov.
    • 26 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Jul 2009 Planned number of patients changed from 40 to 60, additional lead trial investigator (Neijber A) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top